Clinical Trials Browser

Carcinoma, Renal Cell, Lymphoma, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neuroblastoma, Lymphoma, Large-Cell, Anaplastic, Hematologic Neoplasms

NCT04116541 2025-11-21

MegaMOST

Phase 2 Recruiting

455 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04341181 2025-07-25

ProTarget

Phase 2 Recruiting

300 enrolled

Tumor-Agnostic

Neoplasms

NCT05525858 2025-04-27

KOSMOSII

Recruiting

1,000 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Phase 2 Recruiting

770 enrolled

Rare Tumor

NCT04322890 2024-10-22

PIKACHU

Phase 2 Recruiting

6,000 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05014464 2024-09-20

ATPase

Phase 2 Recruiting

90 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06532149 2024-08-09

EROS

Recruiting

80 enrolled

OtherThoracic

Carcinoma, Non-Small-Cell Lung, Eunuchism, Erectile Dysfunction, Sexual Dysfunction, Physiological

NCT05159245 2024-07-15

FINPROVE

Phase 2 Recruiting

250 enrolled

Other hematologic neoplasm

Hematologic Neoplasms

NCT05525338 2024-05-13

ADAPT ALEC

Phase 4 Recruiting

196 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04817956 2024-02-29

IMPRESS-N

Phase 2 Recruiting

3,000 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT02925234 2024-01-24

DRUP

Phase 2 Recruiting

1,550 enrolled

Tumor-Agnostic

Neoplasms

NCT05725200 2023-02-21

EVIDENT

Phase 2 Recruiting

40 enrolled

Gastrointestinal

Colorectal Neoplasms

Clinical Trials

Alectinib Pharmacokinetic in Patients With NSCLC

DURABLE

A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors

Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

ALKAZAR

DETERMINE

DETERMINE

MegaMOST

ProTarget

KOSMOSII

PLATFORM Study of Precision Medicine for Rare Tumors

PIKACHU

ATPase

EROS

FINPROVE

ADAPT ALEC

IMPRESS-N

DRUP

EVIDENT